Literature DB >> 22076285

Fecal occult blood testing when colonoscopy capacity is limited.

Janneke A Wilschut1, J Dik F Habbema, Monique E van Leerdam, Lieke Hol, Iris Lansdorp-Vogelaar, Ernst J Kuipers, Marjolein van Ballegooijen.   

Abstract

BACKGROUND: Fecal occult blood testing (FOBT) can be adapted to a limited colonoscopy capacity by narrowing the age range or extending the screening interval, by using a more specific test or hemoglobin cutoff level for referral to colonoscopy, and by restricting surveillance colonoscopy. Which of these options is most clinically effective and cost-effective has yet to be established.
METHODS: We used the validated MISCAN-Colon microsimulation model to estimate the number of colonoscopies, costs, and health effects of different screening strategies using guaiac FOBT or fecal immunochemical test (FIT) at various hemoglobin cutoff levels between 50 and 200 ng hemoglobin per mL, different surveillance strategies, and various age ranges. We optimized the allocation of a limited number of colonoscopies on the basis of incremental cost-effectiveness.
RESULTS: When colonoscopy capacity was unlimited, the optimal screening strategy was to administer an annual FIT with a 50 ng/mL hemoglobin cutoff level in individuals aged 45-80 years and to offer colonoscopy surveillance to all individuals with adenomas. When colonoscopy capacity was decreasing, the optimal screening adaptation was to first increase the FIT hemoglobin cutoff value to 200 ng hemoglobin per mL and narrow the age range to 50-75 years, to restrict colonoscopy surveillance, and finally to further decrease the number of screening rounds. FIT screening was always more cost-effective compared with guaiac FOBT. Doubling colonoscopy capacity increased the benefits of FIT screening up to 100%.
CONCLUSIONS: FIT should be used at higher hemoglobin cutoff levels when colonoscopy capacity is limited compared with unlimited and is more effective in terms of health outcomes and cost compared with guaiac FOBT at all colonoscopy capacity levels. Increasing the colonoscopy capacity substantially increases the health benefits of FIT screening.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076285     DOI: 10.1093/jnci/djr385

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  38 in total

Review 1.  Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy.

Authors:  Ethna McFerran; James F O'Mahony; Richard Fallis; Duncan McVicar; Ann G Zauber; Frank Kee
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

2.  The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening.

Authors:  Pauline Chauvin; Jean-Michel Josselin; Denis Heresbach
Journal:  Eur J Health Econ       Date:  2013-08-22

3.  Joint breast and colorectal cancer screenings in medically underserved women.

Authors:  Terry C Davis; Connie L Arnold; Michael S Wolf; Charles L Bennett; Dachao Liu; Alfred Rademaker
Journal:  J Community Support Oncol       Date:  2015-02

4.  Third Annual Fecal Occult Blood Testing in Community Health Clinics.

Authors:  Connie L Arnold; Alfred Rademaker; Michael S Wolf; Dachao Liu; Jill Hancock; Terry C Davis
Journal:  Am J Health Behav       Date:  2016-05

5.  Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada.

Authors:  A J Coldman; N Phillips; J Brisson; W Flanagan; M Wolfson; C Nadeau; N Fitzgerald; A B Miller
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

6.  Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy.

Authors:  Barcey T Levy; Camden Bay; Yinghui Xu; Jeanette M Daly; George Bergus; Jeffrey Dunkelberg; Carol Moss
Journal:  J Med Screen       Date:  2014-06-23       Impact factor: 2.136

7.  Fecal immunochemical test accuracy in average-risk colorectal cancer screening.

Authors:  Vicent Hernandez; Joaquin Cubiella; M Carmen Gonzalez-Mao; Felipe Iglesias; Concepción Rivera; M Begoña Iglesias; Lucía Cid; Ines Castro; Luisa de Castro; Pablo Vega; Jose Antonio Hermo; Ramiro Macenlle; Alfonso Martínez-Turnes; David Martínez-Ares; Pamela Estevez; Estela Cid; M Carmen Vidal; Angeles López-Martínez; Elisabeth Hijona; Marta Herreros-Villanueva; Luis Bujanda; Jose Ignacio Rodriguez-Prada
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 8.  Colorectal cancer screening--optimizing current strategies and new directions.

Authors:  Ernst J Kuipers; Thomas Rösch; Michael Bretthauer
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

9.  Strategies to improve repeat fecal occult blood testing cancer screening.

Authors:  Terry C Davis; Connie L Arnold; Charles L Bennett; Michael S Wolf; Cristalyn Reynolds; Dachao Liu; Alfred Rademaker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-05       Impact factor: 4.254

Review 10.  Colorectal cancer.

Authors:  Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe
Journal:  Nat Rev Dis Primers       Date:  2015-11-05       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.